- Home
- VXRT vs LYEL Comparison
VXRT vs LYEL Comparison
Compare VXRT & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VXRT
- LYEL
- Stock Information
- Founded
- VXRT N/A
- LYEL 2018
- Country
- VXRT United States
- LYEL United States
- Employees
- VXRT N/A
- LYEL N/A
- Industry
- VXRT Biotechnology: Biological Products (No Diagnostic Substances)
- LYEL Biotechnology: Pharmaceutical Preparations
- Sector
- VXRT Health Care
- LYEL Health Care
- Exchange
- VXRT Nasdaq
- LYEL Nasdaq
- Market Cap
- VXRT 170.2M
- LYEL 203.9M
- IPO Year
- VXRT N/A
- LYEL 2021
- Fundamental
- Price
- VXRT $0.71
- LYEL $0.70
- Analyst Decision
- VXRT Buy
- LYEL Sell
- Analyst Count
- VXRT 1
- LYEL 2
- Target Price
- VXRT $4.00
- LYEL $1.00
- AVG Volume (30 Days)
- VXRT 1.2M
- LYEL 1.3M
- Earning Date
- VXRT 03-13-2025
- LYEL 03-03-2025
- Dividend Yield
- VXRT N/A
- LYEL N/A
- EPS Growth
- VXRT N/A
- LYEL N/A
- EPS
- VXRT N/A
- LYEL N/A
- Revenue
- VXRT $16,760,000.00
- LYEL $63,000.00
- Revenue This Year
- VXRT $128.77
- LYEL N/A
- Revenue Next Year
- VXRT N/A
- LYEL N/A
- P/E Ratio
- VXRT N/A
- LYEL N/A
- Revenue Growth
- VXRT 303.27
- LYEL N/A
- 52 Week Low
- VXRT $0.52
- LYEL $0.51
- 52 Week High
- VXRT $1.43
- LYEL $3.26
- Technical
- Relative Strength Index (RSI)
- VXRT 48.01
- LYEL 64.48
- Support Level
- VXRT $0.68
- LYEL $0.57
- Resistance Level
- VXRT $0.78
- LYEL $0.63
- Average True Range (ATR)
- VXRT 0.05
- LYEL 0.05
- MACD
- VXRT -0.00
- LYEL 0.02
- Stochastic Oscillator
- VXRT 48.85
- LYEL 87.86
About VXRT Vaxart Inc
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.